Drug-mediated and cellular immunotherapy in multiple myeloma.
Multiple myeloma is an immunologically relevant disease, which subverts and suppresses immunity, but that may also be amenable to immunological control. Novel drug and cell-based therapies provide an opportunity for the design of antimyeloma immunotherapy. Reversing the immunosuppression associated myeloma remains a substantial challenge. The minimal residual disease setting achieved by autologous stem cell transplant or highly efficacious induction therapy may reverse this immunoparesis and provide a setting for induction of antimyeloma T-cell responses. Adoptive cytotoxic T-lymphocyte/NK therapy and comprehensive treatment with immunomodulatory drug therapy represent means by which antimyeloma immune responses may be promoted. In addition, apoptosis-inducing therapies may prime endogenous antigen presentation via immunogenic cell death, which again may be enhanced by the addition of immunomodulatory drug therapy.
Ritchie
David S
DS
Department of Haematology & Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia. david.ritchie@petermac.org
Quach
Hang
H
Fielding
Kate
K
Neeson
Paul
P
D000920:Antibody-Dependent Cell Cytotoxicity; D000951:Antigens, Neoplasm / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D019496:Cancer Vaccines / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005544:Forecasting; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007156:Immunologic Memory; D007167:Immunotherapy / Q000379:methods*; D016233:Immunotherapy, Active; D016219:Immunotherapy, Adoptive; D007694:Killer Cells, Natural / Q000276:immunology / Q000637:transplantation; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy / Q000276:immunology / Q000601:surgery / Q000628:therapy*; D011719:Pyrazines / Q000627:therapeutic use; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000637:transplantation; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D019139:Tumor Escape
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D001897:Boronic Acids; D019496:Cancer Vaccines; D007155:Immunologic Factors; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide